Signal Genetics Expands Reimbursement of MyPRS(R) With Additional Preferred Provider Organization Agreements

CARLSBAD, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the signing of additional preferred provider organization (PPO) agreements.

Under the terms of the agreements, the Signal Genetics MyPRS® assay will be offered through additional PPO networks including the Stratose, USA Managed Care Organization, and Evolutions Healthcare Systems PPO networks. These new agreements will provide coverage to over 21 million patients across the United States.

Tamara A. Seymour, Chief Financial Officer, commented, "We are pleased to continue the expansion of our partnerships with provider networks, as the signing of these agreements will further enhance and simplify our reimbursement process. With strong partnerships and a streamlined reimbursement procedure, we expect to see additional revenue recovery from these initiatives. In addition, these recent agreements demonstrate our ability to continue to execute our growth strategy. Together with the PPO agreement we announced earlier this year and our other payor relationships with Medicare and Blue Cross Blue Shield of Arkansas, the covered lives within our universe has increased to over 93 million patients in the United States."

Signal Genetics has developed its MyPRS® prognostic test to enhance the treatment of patients suffering from multiple myeloma. This proprietary assay enables physicians to accurately stratify patients into high and low-risk categories and molecular disease subtypes, in order to ensure they are receiving the most appropriate level of care to prevent over treating or under treating the disease.

About Signal Genetics, Inc.

Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.

Safe Harbor Statement

This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding our ability to achieve profitability and to penetrate the market opportunity that we believe exists for our prognostic genetic test. Such forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those discussed here, such as our ability to obtain adequate coverage and reimbursement for our tests from third party payors, our ability to obtain necessary regulatory clearances and approvals, the ability of our tests to keep pace with rapid advances in technology, medicine and science, and our ability to execute our marketing strategy and gain acceptance in the market, along with those other risks and uncertainties detailed in our SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date this release and we assume no obligation to update or revise these statements unless otherwise required by law.

CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009

Source:Signal Genetics, Inc.